Testing effectiveness (Phase 2)Ended earlyNCT04434560What this trial is testingNeoadjuvant Immunotherapy in Brain MetastasesWho this might be right forBrain Metastases, Adult Sarah Sammons, MD 1
Early research (Phase 1)Study completedNCT03752398What this trial is testingXmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)Who this might be right forMelanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more Xencor, Inc. 198
Not applicableStudy completedNCT00897533What this trial is testingDevelopment of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung CancerWho this might be right forLung Cancer ECOG-ACRIN Cancer Research Group 137
Testing effectiveness (Phase 2)Study completedNCT01578668What this trial is testingErlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain MetastasesWho this might be right forLung AdenocarcinomaBrain Metastases Guangzhou Medical University 69
Not applicableLooking for participantsNCT05037825What this trial is testingThe Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid TumorsWho this might be right forNon-Small-Cell Lung CarcinomaMalignant MelanomaRenal Cell Carcinoma+1 more VastBiome 800
Early research (Phase 1)Looking for participantsNCT06131840What this trial is testingSGN-CEACAM5C in Adults With Advanced Solid TumorsWho this might be right forColorectal NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms+3 more Seagen, a wholly owned subsidiary of Pfizer 914
Testing effectiveness (Phase 2)Looking for participantsNCT06394674What this trial is testingHigh-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With OsimertinibWho this might be right forNon-Small Cell Lung Cancer Changhai Hospital 84
Testing effectiveness (Phase 2)Looking for participantsNCT06953089What this trial is testingDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsWho this might be right forSolid Tumors DualityBio Inc. 450
Testing effectiveness (Phase 2)Study completedNCT01177397What this trial is testingStudy to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaWho this might be right forMultiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more Celgene 226
Early research (Phase 1)Active Not RecruitingNCT07160335What this trial is testingA Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsWho this might be right forNon-small Cell Lung CancerMelanomaRenal Cell Carcinoma Shanghai Henlius Biotech 174
Testing effectiveness (Phase 2)Ended earlyNCT05194735What this trial is testingPhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsWho this might be right forGynecologic CancerColorectal CancerPancreatic Cancer+9 more Alaunos Therapeutics 8
Testing effectiveness (Phase 2)UnknownNCT03728374What this trial is testingAnlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaWho this might be right forNon-Small-Cell Lung Cancer First Affiliated Hospital of Wenzhou Medical University 38
Testing effectiveness (Phase 2)Study completedNCT03345810What this trial is testingDurvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)Who this might be right forCarcinoma, Non-Small-Cell LungMetastatic Lung CancerNon Small Cell Lung Cancer+2 more AIO-Studien-gGmbH 200
Early research (Phase 1)Study completedNCT01302808What this trial is testingRomidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerWho this might be right forLung CancerMetastatic Cancer University of Texas Southwestern Medical Center 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06648525What this trial is testingAdebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCWho this might be right forIntrahepatic Cholangiocarcinoma (Icc) Harbin Medical University 68
Testing effectiveness (Phase 2)Ended earlyNCT02771626What this trial is testingStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)Who this might be right forClear Cell Renal Cell Carcinoma (ccRCC)MelanomaNon-small Cell Lung Cancer (NSCLC) Calithera Biosciences, Inc 118
Testing effectiveness (Phase 2)Study completedNCT01685138What this trial is testingLDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Novartis Pharmaceuticals 124
Testing effectiveness (Phase 2)UnknownNCT03638206What this trial is testingAutologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesWho this might be right forB-cell Acute Lymphoblastic LeukemiaLymphomaMyeloid Leukemia+13 more Shenzhen BinDeBio Ltd. 73
Early research (Phase 1)Ended earlyNCT05121948What this trial is testingHC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Who this might be right forSquamous Cell Carcinoma of Head and NeckColo-rectal CancerNon Small Cell Lung Cancer+3 more HiberCell, Inc. 35
Early research (Phase 1)Looking for participantsNCT06332755What this trial is testingStudy to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCWho this might be right forNon-small Cell Lung Cancer(NSCLC)Head and Neck Squamous Cell Carcinoma(HNSCC)Renal Cell Carcinoma(RCC)+2 more LG Chem 76